This biweekly Women’s Health recap highlights regulatory progress, clinical data, expanded treatment access, screening initiatives, and emerging oncology developments across breast, cervical, endometrial, and ovarian cancers.
Dive deeper
In Today’s Newsletter
💊 Roche giredestrant gets FDA Priority Review in early breast cancer [1] [US • 02 Jun 2026]
https://www.roche.com/media/releases/med-cor-2026-06-02
Context: The lidERA Phase 3 study showed a 30% reduction in invasive disease recurrence or death versus standard endocrine therapy.
Key point: FDA accepted Roche’s NDA for giredestrant, an oral SERD, as adjuvant therapy for ER-positive, HER2-negative stage I–III breast cancer.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 AstraZeneca camizestrant FDA review extended for SERENA-6 filing [2] [US • 27 May 2026]
https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html
Context: The NDA is based on SERENA-6 Phase 3 data, with additional ctDNA clearance analyses requested after ODAC did not reach a majority vote.
Key point: FDA extended the PDUFA date for camizestrant plus a CDK4/6 inhibitor in 1st-line HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation.
Implication: May influence prescriber choice and payer reviews pending full data.
🎯 Iza-bren Phase 3 data show OS and PFS gains in TNBC and ESCC [3] [China • 02 Jun 2026]
https://news.bms.com/news/corporate-financial/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx
Context: PANKU-Breast02 and PANKU-Esophagus01 evaluated the EGFRxHER3 bispecific ADC against physician’s choice chemotherapy.
Key point: SystImmune and Bristol Myers Squibb reported Phase 3 OS and PFS improvements for iza-bren in TNBC and ESCC.
Implication: May influence prescriber choice and payer reviews pending full data.
🇨🇳 Zai Lab wins China NMPA approval for Tivdak in cervical cancer [4] [China • 08 Jun 2026]
https://www.businesswire.com/news/home/20260608963481/en/Zai-Lab-Receives-China-NMPA-Approval-of-TIVDAK-tisotumab-vedotin-for-injection-for-the-Treatment-of-Adult-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer
Context: Approval is based on innovaTV 301, which showed OS benefit versus chemotherapy, including a consistent China subpopulation trend.
Key point: China NMPA approved Tivdak (tisotumab vedotin) for adults with recurrent or metastatic cervical cancer after chemotherapy.
Implication: Introduces competition that may affect pricing and formulary access.
🏠 Teal Health, WashU launch community HPV self-collection pilot [5] [US • 28 May 2026]
https://www.prnewswire.com/news-releases/teal-health-and-washu-medicine-collaborate-to-expand-cervical-cancer-screening-in-underserved-communities-302784018.html
Context: The study will evaluate kit return, telehealth completion, follow-up after abnormal results, and participant experience in Illinois and Missouri.
Key point: Teal Health and WashU Medicine launched a pilot of at-home HPV self-collection kits distributed through community events.
Implication: May expand screening, initiation, and follow-up at scale.
🇬🇧 NICE recommends Genmab Tivdak for recurrent or metastatic cervical cancer [6] [UK • 28 May 2026]
https://pmlive.com/pharma_news/nice-recommends-genmabs-tivdak-for-recurrent-or-metastatic-cervical-cancer/
Context: The recommendation cites the randomized Phase 3 innovaTV 301 study, with interim Cancer Drugs Fund access planned.
Key point: NICE recommended Genmab UK’s Tivdak for adults with recurrent or metastatic cervical cancer after systemic therapy.
Implication: Introduces competition that may affect pricing and formulary access.
🧪 Puxitatug samrotecan shows activity in B7-H4-positive endometrial cancer [7] [30 May 2026]
https://www.onclive.com/view/puxitatug-samrotecan-elicits-high-response-rate-in-select-endometrial-cancers
Context: BLUESTAR Phase 1/2a data supported FDA Breakthrough Therapy Designation in a prior platinum plus immunotherapy subgroup.
Key point: Puxitatug samrotecan, a B7-H4-directed ADC, showed responses in B7-H4-expressing recurrent or progressive endometrial cancer.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Women’s health oncology remains active across breast, cervical, endometrial, and ovarian cancer.
- Oral SERDs are advancing in ER-positive breast cancer, with regulatory reviews shaping next-step adoption.
- ADC momentum continues across gynecologic cancers and related solid tumors.
- Tivdak’s China approval and NICE recommendation point to broader global access in recurrent or metastatic cervical cancer.
- At-home HPV self-collection could widen screening access for underserved communities.
📚 View the full Women’s health archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.
FAQ
What is Roche’s giredestrant being reviewed for?
FDA accepted Roche’s NDA for giredestrant as adjuvant treatment for ER-positive, HER2-negative stage I–III breast cancer. The PDUFA date is 30 Nov 2026. [1]
Why was AstraZeneca’s camizestrant review extended?
FDA extended the review to assess additional data for camizestrant plus a CDK4/6 inhibitor in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation. [2]
Where is Tivdak gaining access?
Zai Lab received China NMPA approval for Tivdak in recurrent or metastatic cervical cancer, and NICE recommended Genmab UK’s Tivdak for eligible adults in the UK. [4], [6]
What is Teal Health testing with WashU Medicine?
The partners are testing whether at-home HPV self-collection kits distributed through trusted community events can improve cervical cancer screening participation. [5]
What is puxitatug samrotecan?
Puxitatug samrotecan is a B7-H4-directed ADC with a topoisomerase 1 payload, studied in BLUESTAR for advanced solid tumors including endometrial and ovarian cancers. [7]
Entities / Keywords
Women’s health, breast cancer, cervical cancer, endometrial cancer, ovarian cancer
Giredestrant, Roche, oral SERD, ER-positive breast cancer, HER2-negative breast cancer, lidERA
Camizestrant, AstraZeneca, SERENA-6, ESR1 mutation, CDK4/6 inhibitor, ctDNA
Izalontamab brengitecan, iza-bren, SystImmune, Biokin, Bristol Myers Squibb, EGFRxHER3 ADC
Tivdak, tisotumab vedotin, Zai Lab, Genmab, recurrent or metastatic cervical cancer, innovaTV 301
Teal Health, WashU Medicine, Siteman Cancer Center, at-home HPV self-collection
Puxitatug samrotecan, Puxi-Sam, AZD8205, B7-H4 ADC, BLUESTAR
References
- https://www.roche.com/media/releases/med-cor-2026-06-02
- https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html
- https://news.bms.com/news/corporate-financial/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx
- https://www.businesswire.com/news/home/20260608963481/en/Zai-Lab-Receives-China-NMPA-Approval-of-TIVDAK-tisotumab-vedotin-for-injection-for-the-Treatment-of-Adult-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer
- https://www.prnewswire.com/news-releases/teal-health-and-washu-medicine-collaborate-to-expand-cervical-cancer-screening-in-underserved-communities-302784018.html
- https://pmlive.com/pharma_news/nice-recommends-genmabs-tivdak-for-recurrent-or-metastatic-cervical-cancer/
- https://www.onclive.com/view/puxitatug-samrotecan-elicits-high-response-rate-in-select-endometrial-cancers